Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations.

ABSTRACT: Acute myeloid leukemia (AML) with CEBPA bZIP in-frame mutations (CEBPA^bZIP-inf) is classified within the favorable-risk group by the 2022 European LeukemiaNet (ELN-2022). However, heterogeneous clinical outcomes are still observed in these patients. In this study, we aimed to investigate the mutation profiles and transcriptomic patterns associated with poor outcomes in patients with CEBPA^bZIP-inf. One hundred and thirteen CEBPA^bZIP-inf patients were identified in a cohort of 887 AML patients homogeneously treated with intensive chemotherapy. Concurrent WT1 or DNMT3A mutations significantly predicted worse survival in AML patients with CEBPA^bZIP-inf. RNA-sequencing analysis revealed an enrichment of interferon (IFN) signaling and metabolic pathway

SUBMITTER: Tien FM 

PROVIDER: S-EPMC10803338 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature